Humana (NYSE:HUM) Given Neutral Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Humana (NYSE:HUM - Free Report) in a research report released on Wednesday,Benzinga reports. They currently have a $290.00 price target on the insurance provider's stock. Cantor Fitzgerald also issued estimates for Humana's FY2025 earnings at $16.27 EPS.

A number of other research analysts have also weighed in on HUM. TD Cowen upped their price objective on Humana from $261.00 to $268.00 and gave the stock a "hold" rating in a report on Monday, November 4th. Wells Fargo & Company decreased their price objective on Humana from $387.00 to $290.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. Morgan Stanley reduced their target price on Humana from $301.00 to $285.00 and set an "equal weight" rating on the stock in a research report on Wednesday. Bank of America upgraded Humana from an "underperform" rating to a "neutral" rating and increased their target price for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Finally, Piper Sandler raised their price objective on Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a report on Wednesday, January 15th. Nineteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $293.05.

Humana Stock Performance

NYSE HUM traded up $0.73 on Wednesday, reaching $253.61. The stock had a trading volume of 2,386,047 shares, compared to its average volume of 1,515,752. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. Humana has a 12-month low of $213.31 and a 12-month high of $406.46. The business's 50-day moving average price is $271.27 and its 200 day moving average price is $293.44. The stock has a market cap of $30.54 billion, a P/E ratio of 22.46, a price-to-earnings-growth ratio of 2.11 and a beta of 0.56.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 13.20% and a net margin of 1.18%. As a group, equities analysts expect that Humana will post 16.11 earnings per share for the current year.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the firm's stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.32% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Creative Financial Designs Inc. ADV lifted its holdings in Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider's stock worth $27,000 after acquiring an additional 61 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in Humana during the third quarter worth about $31,000. Your Advocates Ltd. LLP lifted its holdings in Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider's stock worth $32,000 after acquiring an additional 45 shares in the last quarter. FPC Investment Advisory Inc. acquired a new stake in shares of Humana in the 4th quarter valued at about $27,000. Finally, Centricity Wealth Management LLC acquired a new stake in shares of Humana in the 4th quarter valued at about $30,000. 92.38% of the stock is currently owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.